Category: Biomarker [1]
Target: GDNF protein [2]
Sample Type: Blood (plasma/serum), CSF [3]
Diseases: Parkinson's Disease, ALS, Huntington's Disease, Spinal Cord Injury, Peripheral Neuropathy [4]
Direction: Decreased in neurodegeneration; therapeutic potential [5]
Sensitivity: pg/mL range in blood [6]
Glial Cell Line-Derived Neurotrophic Factor (GDNF) is a potent neurotrophin that promotes the survival and function of dopaminergic neurons and motor neurons. GDNF was initially discovered for its ability to promote the survival of ventral midbrain dopaminergic neurons, making it a particularly promising therapeutic candidate for Parkinson's disease. It also supports motor neuron survival, with applications in ALS and spinal cord injury. [7]
| Property | Value |
|---|---|
| Gene | GDNF |
| Protein | Glial Cell Line-Derived Neurotrophic Factor |
| UniProt | P39905 |
| Molecular Weight | 15-20 kDa (dimeric) |
| Expression | Astrocytes, neurons, Schwann cells |
| Receptors | GFRα1/RET, GFRα2/RET, GFRα3/RET |
| Function | Dopaminergic/Motor neuron survival, neurite outgrowth |
| Disease | GDNF Level | Correlation | Utility |
|---|---|---|---|
| PD | Decreased | Motor severity | Monitoring |
| ALS | Decreased | Progression | Prognosis |
| HD | Decreased | Disease stage | Monitoring |
| SCI | Variable | Injury severity | Prognosis |
| Trial | Phase | Status | Indication |
|---|---|---|---|
| AAV-GDNF (Voyager) | Phase 1-2 | Completed | PD |
| AAV-GDNF (Prevail) | Phase 1-2 | Ongoing | PD |
| Intranasal GDNF | Phase 1-2 | Ongoing | PD |
Recent studies explore GDNF alongside other Parkinson's biomarkers including:
New AAV vectors with enhanced CNS tropism show promise for GDNF delivery, potentially overcoming blood-brain barrier limitations.
GDNF receptor expression levels (GFRα1, GFRα2, RET) may predict therapeutic response, enabling personalized treatment approaches.
GDNF represents a promising neurotrophic factor biomarker for neurodegenerative diseases, particularly Parkinson's disease. While challenges remain regarding CNS penetration and receptor dependency, ongoing gene therapy trials and biomarker combination approaches offer hope for clinical utility. Monitoring GDNF levels alongside other disease markers may provide valuable insights into disease progression and treatment response.
The study of Gdnf Neurotrophic Factor Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Airaksinen MS, et al. GDNF family of neurotrophic factors (2002). 2002. ↩︎
Kordower JH, et al. GDNF in Parkinson disease (2000). 2000. ↩︎
Saarma M, et al. GDNF and Parkinson disease (2006). 2006. ↩︎
Nightingale S, et al. GDNF clinical trials (2004). 2004. ↩︎
Ramadan R, et al. GDNF in neuroprotection (2020). 2020. ↩︎
Bartus RT, et al. GDNF for Parkinson disease (2011). 2011. ↩︎
Sullivan AM, et al. GDNF and aging (2016). 2016. ↩︎